ArticleJACC. Advances2026
Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData are lacking on left ventricular ejection fraction (LVEF) trajectory following myocardial infarction (MI).
objectivesThis study aimed to evaluate the impact of LVEF trajectory after percutaneous coronary intervention (PCI) for MI on long-term outcomes.
methodsPatients undergoing PCI for MI (2007-2022) with serial echocardiograms were identified in the Swedish Coronary Angiography and Angioplasty Registry and the UC San Diego internal National Cardiovascular Data Registry CathPCI Registry. All-cause mortality and heart failure hospitalization within 6 years were assessed with time-to-event analysis adjusted for baseline characteristics.
resultsOf 13,439 patients (mean age 64 ± 10 years, 24.5% female, 46.8% ST-segment elevation MI), 28.2% had consistently reduced LVEF (redEF), 14.8% recovered their LVEF (recEF), 53.0% had consistently preserved LVEF (pEF), and 3.9% decreased from preserved to reduced LVEF (decEF). Heart failure hospitalization rates were 40.0% for redEF, 30.4% for decEF, 16.1% for recEF, and 6.4% for pEF (P < 0.001). Compared to pEF, the heart failure hospitalization risk was significantly higher for redEF (adjusted HR [aHR]: 8.49; 95% CI: 7.49-9.64; P < 0.001), decEF (aHR: 5.74; 95% CI: 4.69-7.02; P < 0.001), and recEF (aHR: 3.18; 95% CI: 2.70-3.76; P < 0.001). Mortality rates were 14.0% for redEF, 14.9% for decEF, 7.8% for recEF, and 6.7% for pEF (P < 0.001). Compared to pEF, the mortality risk was significantly higher for redEF (aHR: 2.20; 95% CI: 1.86-2.59; P < 0.001), decEF (aHR: 2.10; 95% CI: 1.56-2.82; P < 0.001), and recEF (aHR: 1.30; 95% CI: 1.02-1.65; P = 0.032).
conclusionsLVEF trajectory after MI significantly impacts long-term outcomes. Even patients with LVEF recovery remain at increased risk for heart failure hospitalization and mortality compared to those with pEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.